Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SLN360
Zerlasiran (SLN360) · 1 trial · 3 indications
safety and tolerability will be reported separately following single-dose administration.
| Arm | Type | Description |
|---|---|---|
| 30 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 100 mg | EXPERIMENTAL | - |
| 300 mg | EXPERIMENTAL | - |
| 600 mg | EXPERIMENTAL | - |
| 900 mg | EXPERIMENTAL | - |
| 100 mg multi dose | EXPERIMENTAL | - |
| 200 mg multi dose | EXPERIMENTAL | - |
| 300 mg multi dose | EXPERIMENTAL | - |
| 600 mg multi dose | EXPERIMENTAL | - |
| Placebo multi dose | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SLN360 | DRUG | SLN360 for subcutaneous (s.c.) injection |
| Placebo | DRUG | Sodium chloride for subcutaneous (s.c.) injection |
Inclusion criteria: * Elevated plasma Lp(a) ≥ 150nmol/L. * All subjects must agree to adhere to appropriate contraception requirements. * Subjects must provide written informed consent and be able to comply with all study requirements. * Body mass index of ≥ 18 kg/m2 and ≤ 45 kg/m2. * For the MD pa...
Zerlasiran is an investigational RNA therapy being developed for hyperlipidemias, including dyslipidemias and elevated lipoprotein(a). It is designed to reduce elevated Lp(a) levels in adults. It has not been approved for any indication and remains in clinical development.
Zerlasiran is a small interfering RNA (siRNA) therapy. It targets the production of lipoprotein(a) to lower elevated Lp(a) levels. By silencing specific RNA, it aims to reduce the synthesis of this lipoprotein. This mechanism is characteristic of the -siran class of RNA therapies.
Zerlasiran is being developed by Silence Therapeutics Plc, whose American Depositary Shares trade on the Nasdaq under the ticker SLN. The company is responsible for the clinical development of the drug.
Zerlasiran is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any regulatory agency. The Phase 1 trial has been completed.
Zerlasiran has been studied in one completed Phase 1 trial, NCT04606602, titled "Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)." It enrolled 70 participants across the United States, Australia, Netherlands, and United Kingdom.
Yes, Zerlasiran is also known as SLN360. SLN360 is the original code name for the same investigational siRNA therapy developed by Silence Therapeutics. Both names refer to the identical drug candidate.